Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PARD3_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PARD3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PARD3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PARD3_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PARD3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/PARD3_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PARD3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PARD3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PARD3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PARD3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PARD3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PARD3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00181072 | Colorectum | FAP | peptidyl-threonine phosphorylation | 29/2622 | 116/18723 | 1.12e-03 | 1.08e-02 | 29 |
GO:00451973 | Colorectum | FAP | establishment or maintenance of epithelial cell apical/basal polarity | 14/2622 | 44/18723 | 1.99e-03 | 1.67e-02 | 14 |
GO:00350883 | Colorectum | FAP | establishment or maintenance of apical/basal cell polarity | 15/2622 | 49/18723 | 2.15e-03 | 1.77e-02 | 15 |
GO:00612453 | Colorectum | FAP | establishment or maintenance of bipolar cell polarity | 15/2622 | 49/18723 | 2.15e-03 | 1.77e-02 | 15 |
GO:00901622 | Colorectum | FAP | establishment of epithelial cell polarity | 11/2622 | 31/18723 | 2.26e-03 | 1.84e-02 | 11 |
GO:00708303 | Colorectum | FAP | bicellular tight junction assembly | 19/2622 | 70/18723 | 2.84e-03 | 2.18e-02 | 19 |
GO:0061842 | Colorectum | FAP | microtubule organizing center localization | 11/2622 | 33/18723 | 3.95e-03 | 2.75e-02 | 11 |
GO:0006612 | Colorectum | FAP | protein targeting to membrane | 30/2622 | 131/18723 | 3.95e-03 | 2.75e-02 | 30 |
GO:00071634 | Colorectum | CRC | establishment or maintenance of cell polarity | 57/2078 | 218/18723 | 3.96e-10 | 1.58e-07 | 57 |
GO:00300104 | Colorectum | CRC | establishment of cell polarity | 40/2078 | 143/18723 | 2.09e-08 | 3.23e-06 | 40 |
GO:00343294 | Colorectum | CRC | cell junction assembly | 83/2078 | 420/18723 | 1.08e-07 | 1.29e-05 | 83 |
GO:00452165 | Colorectum | CRC | cell-cell junction organization | 48/2078 | 200/18723 | 1.67e-07 | 1.72e-05 | 48 |
GO:00074094 | Colorectum | CRC | axonogenesis | 81/2078 | 418/18723 | 3.60e-07 | 2.99e-05 | 81 |
GO:00516564 | Colorectum | CRC | establishment of organelle localization | 76/2078 | 390/18723 | 6.53e-07 | 4.50e-05 | 76 |
GO:00615644 | Colorectum | CRC | axon development | 86/2078 | 467/18723 | 1.48e-06 | 8.12e-05 | 86 |
GO:00516603 | Colorectum | CRC | establishment of centrosome localization | 7/2078 | 10/18723 | 1.82e-05 | 5.47e-04 | 7 |
GO:00901505 | Colorectum | CRC | establishment of protein localization to membrane | 51/2078 | 260/18723 | 3.59e-05 | 9.05e-04 | 51 |
GO:00181073 | Colorectum | CRC | peptidyl-threonine phosphorylation | 27/2078 | 116/18723 | 1.38e-04 | 2.58e-03 | 27 |
GO:00182103 | Colorectum | CRC | peptidyl-threonine modification | 28/2078 | 125/18723 | 2.10e-04 | 3.55e-03 | 28 |
GO:00070435 | Colorectum | CRC | cell-cell junction assembly | 31/2078 | 146/18723 | 2.75e-04 | 4.40e-03 | 31 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PARD3 | SNV | Missense_Mutation | | c.3714N>G | p.Asp1238Glu | p.D1238E | Q8TEW0 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.99) | TCGA-AR-A1AQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PARD3 | SNV | Missense_Mutation | rs566752362 | c.2728N>T | p.Arg910Cys | p.R910C | Q8TEW0 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AR-A1AV-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD |
PARD3 | SNV | Missense_Mutation | | c.1741N>A | p.Asp581Asn | p.D581N | Q8TEW0 | protein_coding | deleterious(0.03) | benign(0.116) | TCGA-D8-A1XJ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
PARD3 | SNV | Missense_Mutation | | c.2826N>A | p.Asp942Glu | p.D942E | Q8TEW0 | protein_coding | tolerated(0.12) | probably_damaging(0.992) | TCGA-E2-A15T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PARD3 | insertion | Frame_Shift_Ins | novel | c.3814_3815insTTTTTTTAAAACCTCGATGGTACTATGGAGTATTTCTGTTGTT | p.Gly1272ValfsTer54 | p.G1272Vfs*54 | Q8TEW0 | protein_coding | | | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | | SD |
PARD3 | insertion | Nonsense_Mutation | novel | c.1625_1626insATTAATTATACAAATATAGGTCTTGTTACTTAGGATGACA | p.Val544IlefsTer5 | p.V544Ifs*5 | Q8TEW0 | protein_coding | | | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PARD3 | SNV | Missense_Mutation | rs768549956 | c.3613C>T | p.Arg1205Trp | p.R1205W | Q8TEW0 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.928) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PARD3 | SNV | Missense_Mutation | novel | c.2885C>A | p.Ser962Tyr | p.S962Y | Q8TEW0 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PARD3 | SNV | Missense_Mutation | | c.3253G>C | p.Asp1085His | p.D1085H | Q8TEW0 | protein_coding | tolerated(0.12) | probably_damaging(0.999) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
PARD3 | SNV | Missense_Mutation | rs377613171 | c.3701C>T | p.Ser1234Leu | p.S1234L | Q8TEW0 | protein_coding | deleterious_low_confidence(0.01) | benign(0.124) | TCGA-EA-A50E-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |